Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous NSCLC
NCT07771764Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Major Pathological Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07771764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771764.